Cargando…
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagon...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177151/ https://www.ncbi.nlm.nih.gov/pubmed/35575456 http://dx.doi.org/10.7554/eLife.72512 |
_version_ | 1784722830166851584 |
---|---|
author | Hosfield, David J Weber, Sandra Li, Nan-Sheng Sauvage, Madline Joiner, Carstyn F Hancock, Govinda R Sullivan, Emily A Ndukwe, Estelle Han, Ross Cush, Sydney Lainé, Muriel Mader, Sylvie C Greene, Geoffrey L Fanning, Sean W |
author_facet | Hosfield, David J Weber, Sandra Li, Nan-Sheng Sauvage, Madline Joiner, Carstyn F Hancock, Govinda R Sullivan, Emily A Ndukwe, Estelle Han, Ross Cush, Sydney Lainé, Muriel Mader, Sylvie C Greene, Geoffrey L Fanning, Sean W |
author_sort | Hosfield, David J |
collection | PubMed |
description | Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug’s antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated Laso derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles. |
format | Online Article Text |
id | pubmed-9177151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-91771512022-06-09 Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells Hosfield, David J Weber, Sandra Li, Nan-Sheng Sauvage, Madline Joiner, Carstyn F Hancock, Govinda R Sullivan, Emily A Ndukwe, Estelle Han, Ross Cush, Sydney Lainé, Muriel Mader, Sylvie C Greene, Geoffrey L Fanning, Sean W eLife Biochemistry and Chemical Biology Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug’s antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated Laso derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles. eLife Sciences Publications, Ltd 2022-05-16 /pmc/articles/PMC9177151/ /pubmed/35575456 http://dx.doi.org/10.7554/eLife.72512 Text en © 2022, Hosfield et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Biochemistry and Chemical Biology Hosfield, David J Weber, Sandra Li, Nan-Sheng Sauvage, Madline Joiner, Carstyn F Hancock, Govinda R Sullivan, Emily A Ndukwe, Estelle Han, Ross Cush, Sydney Lainé, Muriel Mader, Sylvie C Greene, Geoffrey L Fanning, Sean W Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title_full | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title_fullStr | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title_full_unstemmed | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title_short | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells |
title_sort | stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in esr1 mutant breast cancer cells |
topic | Biochemistry and Chemical Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177151/ https://www.ncbi.nlm.nih.gov/pubmed/35575456 http://dx.doi.org/10.7554/eLife.72512 |
work_keys_str_mv | AT hosfielddavidj stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT webersandra stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT linansheng stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT sauvagemadline stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT joinercarstynf stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT hancockgovindar stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT sullivanemilya stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT ndukweestelle stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT hanross stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT cushsydney stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT lainemuriel stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT madersylviec stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT greenegeoffreyl stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells AT fanningseanw stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells |